SCHEMBL4527461

SCHEMBL4527461

CC(C)(C)OC(=O)N(c1ccc(-c2ccncc2)cc1)[C@@H](Cc1ccc(F)cc1)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.41
CYP17A1 P05093 1/20 0.39
GPR142 Q7Z601 1/20 0.37
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MME P08473 2/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
ROCK1 Q13464 1/20 0.36
ACE P12821 1/20 0.36
ALOX5 P09917 1/20 0.36
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35
MGLL Q99685 1/20 0.35
FPR2 P25090 1/20 0.35
SCN9A Q15858 1/20 0.35
KMT2A Q03164 2/20 0.35
MAPK14 Q16539 2/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514379 1.00 GRM2 (0.41) GRM2CYP17A1GPR142MMP2MMP3
SCHEMBL4526796 0.91 KIF11 (0.39) CYP17A1ROCK1MGLLAAK1
SCHEMBL4517315 0.90 ROCK2 (0.44) CYP17A1GPR142MMEROCK1ACE
SCHEMBL4533235 0.89 CYP17A1 (0.39) CYP17A1GPR142ROCK1MGLLMMP12
SCHEMBL4519180 0.89 GPR142 (0.41) CYP17A1GPR142ROCK1KMT2AMEN1
SCHEMBL4524959 0.88 ROCK1 (0.51) GRM2CTSSCTSKROCK1MGLL
SCHEMBL4523329 0.87 GPR142 (0.40) CYP17A1GPR142MMP2CTSSCTSK
SCHEMBL4516266 0.86 NPC1 (0.39) CYP17A1ROCK1KMT2AMEN1ALDH1A1
SCHEMBL4512483 0.84 CTSS (0.38) CYP17A1CTSSCTSKROCK1MGLL
SCHEMBL4514249 0.82 ROCK2 (0.37) ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211919-B2 Amide derivatives as rock inhibitors ASTELLAS PHARMA INC. (JP) 2012-07-03 US disclosed
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2009-04-23 US disclosed
EP-1922306-A2 AMIDE DERIVATIVES AS ROCK INHIBITORS Astellas Pharma Inc. (JP) 2008-05-21 EP disclosed
WO-2007026920-A2 AMIDE DERIVATIVES AS ROCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105231-A1 AMIDE DERIVATIVES AS ROCK INHIBITORS ROCK1, ROCK2, RHOA GRM2 2431/4885CYP17A1 3015/4885GPR142 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.